ARA-290 (Cibinetide): Mechanism and Research Evidence

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

ARA-290, also called cibinetide, is a short synthetic peptide derived from erythropoietin (EPO). It was engineered to keep EPO’s tissue-protective signalling while removing the part of the molecule responsible for making red blood cells. That single design decision is what makes it interesting to researchers: it allows the protective side of EPO biology to be studied without the haematological effects — rising haematocrit and thrombotic risk — that limit high-dose EPO in experimental models.

This article pulls together what the published record currently shows about ARA-290: how it signals, what has been observed in chemotherapy-toxicity models, what has come out of the small human trials completed to date, and which questions are still open. Everything below describes laboratory and clinical research. Nothing here is guidance for use in humans or animals.

What is ARA-290?

ARA-290 is an 11-amino-acid peptide modelled on a helical region of the erythropoietin molecule. Full-length EPO has two distinct signalling jobs. Through the classical homodimeric EPO receptor it drives erythropoiesis. Through a second, separate receptor complex it drives tissue protection and repair. ARA-290 was built to engage only the second.

Because it is a small linear peptide rather than a full glycoprotein, ARA-290 has a short circulating half-life and does not accumulate the way EPO does. In research settings it has been examined by systemic administration in rodents and by subcutaneous administration in the small human trials that have been run.

How does ARA-290 signal without triggering erythropoiesis?

The target is the innate repair receptor (IRR) — a heteromeric complex of the EPO receptor and the β-common receptor (βcR), the shared subunit used by the GM-CSF, IL-3 and IL-5 receptors. The IRR is largely absent from healthy resting tissue and is expressed in response to injury, hypoxia and inflammatory stress. That expression pattern is why ARA-290 is described as acting selectively at damaged tissue.

Reported downstream consequences of IRR engagement include:

• Pro-survival signalling. IRR ligation activates JAK2 and downstream anti-apoptotic programmes, and promotes eNOS phosphorylation and associated reparative signalling.
• Suppression of inflammatory cascades. NF-κB transcriptional activity, p38 MAPK and GSK-3β signalling are dampened, with corresponding reductions in TNF-α and IL-1β.
• No erythropoietic drive. Because the classical homodimeric EPO receptor is not the target, red cell production is not stimulated at studied concentrations.

A second mechanism has also been proposed in the neurological literature — antagonism at adenosine A_2A receptors, which modulate dopaminergic and glutamatergic tone in the striatum. This is a less well established line of evidence than the IRR work and should be treated as a hypothesis rather than a settled mechanism.

What has been observed in chemotherapy-toxicity models?

The most detailed in vitro work on ARA-290 concerns doxorubicin (DOX), an anthracycline whose clinical usefulness is limited by damage to healthy tissue, particularly cardiac muscle. Shokrzadeh and colleagues examined whether ARA-290 could reduce that collateral damage.^[1]

Their reported findings:

• Concentration-dependent genoprotection. ARA-290 lowered DOX-induced DNA damage in non-malignant cells, measured by comet assay (DNA in tail) and micronucleus frequency.
• Restored antioxidant defence. Reactive oxygen species generation fell, while superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity rose.
• Reduced inflammatory and apoptotic signalling. NF-κB activation and pro-inflammatory cytokine output were attenuated, along with TRAIL-sensitised apoptotic signalling.

Did it protect the tumour cells too?

This is the question that decides whether the model is interesting at all, and it is worth stating carefully. In the comparative assays reported, ARA-290 preserved doxorubicin’s cytotoxicity against cancer cell lines while improving viability and genomic integrity in non-malignant and stem/progenitor cells exposed to the same drug.^[1] The proposed explanation is that functional EPO/IRR signalling is minimal in many tumour lines, which express very low EpoR transcript levels relative to normal tissue.

That is a cell-culture result. Whether the same separation holds in a living organism, across tumour types, and over a full treatment course has not been established. Targeted in vivo validation is the obvious next step, and it has not yet been published at scale.

What does the broader anti-inflammatory literature show?

ARA-290 sits inside a wider body of work on EPO-derived tissue-protective peptides. A systematic review of non-clinical in vivo studies found a consistent pattern across diverse animal models.^[2] Reported effects included reduced leukocyte infiltration; down-modulation of TNF-α, IL-1β, IFN-γ and IL-6; increased IL-10 and TGF-β; mitigation of sepsis-related nitric oxide overproduction with improved endothelial function; and attenuated neuroinflammation after brain injury and in autoimmune neuritis.

The breadth is notable, but breadth in animal models is not the same as demonstrated clinical benefit. Systematic reviews of preclinical work also tend to inherit publication bias from the underlying literature.

What has ARA-290 shown in human trials?

Human data on ARA-290 remain limited to small, early-phase studies. Three are worth knowing about.

Sarcoidosis-associated small fibre neuropathy

The best-developed clinical indication is neuropathic pain in sarcoidosis, an area with few effective non-opioid options. Trial work reported reductions in moderate-to-severe neuropathic pain and improved quality of life without major safety signals.^[3] ARA-290 received Orphan Drug Designation for this indication.

Type 2 diabetes with neuropathic symptoms

Brines and colleagues ran a 28-day placebo-controlled study in participants with type 2 diabetes and reported improvements in metabolic control, lipid profile and neuropathic symptom scores.^[4] The result that drew the most attention was an increase in corneal nerve fibre density — a structural measure, not a symptom questionnaire, which suggests peripheral nerve regeneration rather than analgesia alone. The study was small and short, and the finding has not been replicated in a large trial.

Diabetic macular edema (Phase 2)

A 12-week Phase 2 study of cibinetide in diabetic macular edema reported good tolerability alongside improvements in vision-related quality of life, central retinal thickness, tear production and some metabolic and renal markers in subsets of participants.^[5] The authors framed it as supporting further trials rather than as demonstrating efficacy — a distinction worth preserving when the study is cited.

Emotional and cognitive processing

A controlled human neuropsychological study tested whether ARA-290 behaves like an antidepressant. It reported altered neural processing of emotional stimuli and increased attentional bias toward positive cues, but did not confirm consistent mood benefit.^[6] The honest summary is that the signal is interesting and the conclusion is unresolved.

What is the evidence in neurodegeneration models?

In APP/PS1 transgenic mice, early systemic ARA-290 was reported to improve cognition and slow amyloid-β pathology.^[7] The proposed mechanism is immunological rather than direct: ARA-290 expanded the Ly6C^low patrolling monocyte population and increased monocyte progenitors in bone marrow, enhancing vascular clearance of amyloid-β and lowering overall brain burden.

The timing finding matters more than the headline. Effects were diminished in aged mice with advanced pathology. That points to a narrow intervention window early in the disease process and is consistent with the broader literature on innate immune cells as therapeutic targets in Alzheimer’s disease and multiple sclerosis.^[8]

Research material

How should ARA-290 be handled in the laboratory?

ARA-290 is supplied as a lyophilised powder. General handling practice for research peptides applies:

• Storage of the lyophilised powder. Keep at −20 °C, protected from light and moisture. Allow the vial to reach room temperature before opening to avoid condensation.
• After reconstitution. Store refrigerated and use within a short window; repeated freeze–thaw cycles degrade peptides. Aliquot rather than re-freezing a single vial.
• Documentation. Record lot number, reconstitution date, solvent and concentration against every experimental run. Batch traceability is what makes a result reproducible by anyone else.
• Verification. Match the certificate of analysis to the lot number on the vial in hand, not to a generic COA for the product line.

Frequently asked questions

Is ARA-290 the same thing as EPO?

No. ARA-290 is an 11-amino-acid peptide modelled on part of the EPO molecule. It engages the innate repair receptor rather than the classical erythropoietin receptor, and does not stimulate red blood cell production at studied concentrations.

Why is ARA-290 also called cibinetide?

Cibinetide is the international non-proprietary name assigned to the peptide. Published clinical work — the diabetic macular edema trial in particular — generally uses “cibinetide”, while preclinical literature more often uses “ARA-290”. They refer to the same molecule.

Has ARA-290 been approved by any regulator?

No. It holds Orphan Drug Designation for sarcoidosis-associated neuropathic pain, which is a development incentive, not a marketing approval. It remains investigational.

What is the strongest single piece of evidence so far?

Arguably the corneal nerve fibre density increase reported in the type 2 diabetes study,^[4] because it is an objective structural measure rather than a subjective score. It is also a small, short study — the strongest available evidence is not the same as strong evidence.

What are the main open questions?

Durability of effect; whether the tumour-selectivity seen in cell culture holds in vivo; and long-term safety across a nuclear receptor–adjacent signalling pathway. All of these require controlled clinical trials that have not yet been run.

Where the evidence stands

ARA-290 is an investigational IRR agonist with a coherent mechanistic story and a scattered evidence base. The in vitro work on doxorubicin genotoxicity is the most detailed dataset available; the type 2 diabetes and sarcoidosis studies are the most meaningful human signals; the Alzheimer’s model work is early and timing-dependent. What is missing is scale — larger, longer, controlled trials with predefined endpoints.

For research purposes, that combination is exactly what makes the peptide useful: a well-defined receptor target, a reproducible cellular readout, and a set of unanswered questions that can be designed around. ARA-290 should be used for research only.

Sources

1. Shokrzadeh M, et al. “An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.” Toxicology in Vitro, 2020;66:104864. doi:10.1016/j.tiv.2020.104864
2. Silva I, et al. “Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: a systematic review.” Biomedicine & Pharmacotherapy, 2021;139:111558. doi:10.1016/j.biopha.2021.111558
3. Niesters M, Swartjes M, Heij L, Brines M, Cerami A, Dunne A, et al. “The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain.” Expert Opinion on Orphan Drugs, 2013;1(1):77–87. doi:10.1517/21678707.2013.719289
4. Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Molecular Medicine, 2015;20(1):658–666. doi:10.2119/molmed.2014.00215
5. Lois N, et al. “A Phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema.” Journal of Clinical Medicine, 2020;9(7):2225. doi:10.3390/jcm9072225
6. Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW, et al. “Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.” European Neuropsychopharmacology, 2015;25(12):2289–2299. doi:10.1016/j.euroneuro.2015.09.005
7. Al-Onaizi MA, et al. “Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.” Brain, Behavior, and Immunity, 2021. doi:10.1016/j.bbi.2021.07.016
8. Fani Maleki A, Rivest S. “Innate immune cells: monocytes, monocyte-derived macrophages and microglia as therapeutic targets for Alzheimer’s disease and multiple sclerosis.” Frontiers in Cellular Neuroscience, 2019;13:355. doi:10.3389/fncel.2019.00355